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Simple Summary: Based on the four molecular subtypes of pancreatic cancer described by Bailey
et al. 2016, in the present article we match the molecular, histology and microenvironment features of
pancreatic cancer. This approach may help to understand the molecular basis of this kind of tumor,
and how their microenvironment may affect treatment response. Moreover, we compile information
about crucial factors that could serve as potential targets for drug design to achieve higher anti-tumor
activity, and how histological evaluation of tumor microenvironment could provide first signs about
treatment response.
Abstract: In the last decade, several studies based on whole transcriptomic and genomic analyses of
pancreatic tumors and their stroma have come to light to supplement histopathological stratification
of pancreatic cancers with a molecular point-of-view. Three main molecular studies: Collisson et al.
2011, Moffitt et al. 2015 and Bailey et al. 2016 have found specific gene signatures, which identify
different molecular subtypes of pancreatic cancer and provide a comprehensive stratification for both
a personalized treatment or to identify potential druggable targets. However, the routine clinical
management of pancreatic cancer does not consider a broad molecular analysis of each patient, due
probably to the lack of target therapies for this tumor. Therefore, the current treatment decision is
taken based on patients´ clinicopathological features and performance status. Histopathological
evaluation of tumor samples could reveal many other attributes not only from tumor cells but also
from their microenvironment specially about the presence of pancreatic stellate cells, regulatory
T cells, tumor-associated macrophages, myeloid derived suppressor cells and extracellular matrix
structure. In the present article, we revise the four molecular subtypes proposed by Bailey et al.
and associate each subtype with other reported molecular subtypes. Moreover, we provide for each
subtype a potential description of the tumor microenvironment that may influence treatment response
according to the gene expression profile, the mutational landscape and their associated histology.
Keywords: molecular subtypes of pancreatic cancer; microenvironment; chemotherapy response;
pancreatic stellate cells; regulatory T cells; tumor-associated macrophages; myeloid derived suppres-
sor cells
1. Introduction
Pancreatic cancer (PC) incidence has increased in developed countries and its trend for
2030 is to be higher reaching the second cause of cancer-related deaths [1]. When tumors are
<2 cm in size, the 5-year survival rate is around 50% while for tumors <1 cm could average
as much as 100% [2]. Regrettably, pancreatic cancer symptoms are often misdiagnosed
and commonly treated ambulatory that leads to a late diagnosis with metastatic disease
in distant organs; then, their 5-year survival rate decreased to 3% [3,4]. PC could be
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detected by elevated levels of CA19-9 serum marker [5]. However, CA19-9 is not PC
specific and its levels are also high after biliary obstruction [6]. Recently, CA19-9 serum
level in combination with IGF-1 and albumin have increased the sensitivity up to 93.6%
and the specificity up to 95% to identify PC patients [7].
Risk factors of PC are cigarette smoking associated to 20–25% cases [8,9], chronic
pancreatitis (4%) [10], diabetes (30%) [11], and some infectious agents like Helicobacterpylori
(65%) presents an increased risk [12].
Surgical resection is considered the best treatment approach against PC. Histopatho-
logical characteristics of resected tumor like margins of resection (R), differentiation of
tumor cells (G) or lymph-node status (N) could predict patient prognosis [13]. After resec-
tion, adjuvant treatment will depend on patient performance status but is usually based
on gemcitabine [14], 5-fluorouracil and their combination with other cytotoxics [15]. The
combination of gemcitabine with capecitabine exhibited better survival rates [16]. Other
regimens based on FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin)
or gemcitabine in combination with nano-albumin-bound paclitaxel (nab-paclitaxel) is
administered to borderline resectable tumors as neoadjuvant treatment [17]. Another
option for R1 patients, borderline resectable or locally advanced unresectable tumors is
chemoradiotherapy [18,19]. However, PC exhibits chemoresistance due to a complex link
between tumor cells and their microenvironment [20]. The tumor microenvironment TME
is referred to the local environment where tumors developed [21]. The TME of PC is
composed by tumor cells, extracellular matrix and stromal cells (pancreatic stellate cells
(PSCs), regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid
derived suppressor cells (MDSCs). All these TME components foster high levels of hypoxia,
which confer several metabolic advantages to tumor cells. Some studies have shown how
PC microenvironment regulates proliferation, invasion and metastasis, chemoresistance
and immune evasion [22,23].
Microenvironment of PC has immunosuppressive characteristics that lead to escape
from the immune system, which enhances tumor progression. Cell populations from TME
could induce the deposition of extracellular molecules such as matrix metalloproteinases,
extracellular matrix molecules, growth factors and transforming growth factor β (TGF-β)
to maintain the enabling microenvironment [24]. PSCs are able to produce a collagenous
stroma and its role is crucial in both normal pancreas and tumor development. PSCs
cooperate with cancer cells to build a perfect niche of tumor development with invasive
abilities [25]. While in a normal physiological state, PSCs are quiescent and express nestin,
vimentin, GFAP and desmin; activated PSCs become myofibroblast-like cells with overex-
pression of collagen type I and III, fibronectin and laminin, and present high proliferation
and migration abilities [26]. Furthermore, activated PSCs allow pancreatic cancer-related
fibrosis [27]. Interestingly, PSCs with an activated phenotype present expression of α-
SMA [26], while CD10 positive PSCs have the ability to promote an invasive phenotype
in PC [28]. There are subgroups of PSCs that interact with pancreatic β-cells called islet
stellate cells. These islets are able to induce β-cell apoptosis, inhibit their proliferation,
and diminish β-cell function [29,30]. Indeed, activated PSCs could impair pancreatic islet
endocrine function. Since PSCs are glucose intolerant, this cell population is involved in
development of type 2 diabetes, which directly promotes invasive phenotype because high
levels of glucose are related to epithelial-to-mesenchymal transition [29,31]. PSCs promote
also epithelial-to-mesenchymal transition of PC tumor cells [26].
Another TME cell population is Tregs that are a CD4+T cells subpopulation generated
from naïve T cells with expression of FOXP3 and CD25.They are present in TME and they
are able to suppress autoimmunity in physiological conditions, but also inhibit anti-tumor
immune response. This fact could be explained because Tregs can impact tumor-associated
CD11c+ dendritic cells to inhibit the activation of CD8+ T cells [32]. Recently, it has been
described how Tregs induce differentiation of cancer-associated fibroblasts that promote
tumor development [33]. Shevchenko et al. reported that gemcitabine at low doses reduce
Tregs population in PC and provide a modest increase in survival [34]. Another study
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described how neutrophil-lymphocyte ratio and a high proportion of Treg cells in pan-
creatic tumors are potential pathological biomarkers for poor outcome [35]. On the other
hand, TAMs imply a subtype of immune cells that are commonly expressed in several solid
tumors, and closely related to cancer-derived inflammation. Specially M2-polarized TAMs
(CD163+ cells) are those cells with direct implication in cancer-derived inflammation; in ad-
dition, M2-polarized TAMs enable epithelial-to-mesenchymal transition through activation
of TLR4/IL-10 signaling and inhibition of E-cadherin [36]. Additionally, TAMs promote
angiogenesis, dedifferentiation and stem-cell phenotype in PC [37]. TAMs show several
tumor-prone characteristics based on the release of some immunosuppressive and angio-
genic cytokines [38]. In PC, TAMs present a high expression of BMP-4, BMP-7, TGF-β1 and
TGF-β2 [39]. The infiltration of M2-polarized TAMs in PC stroma seems to be preferentially
located in the body and tail of the pancreas, and similarly with other TME cell populations,
M2-polarized TAM confers shorter overall survival to patients [40]. It has been reported
how metformin could reduce desmoplasia of PC, reversion of epithelial-to-mesenchymal
transition, and tumor-related inflammation via modulation of the AMPK/STAT3 that
decreases levels of IL-1β and hampers infiltration of M2-polarized TAMs [41]. Indeed,
metformin in combination with simvastatin and digoxin is being evaluated in a phase IB
trial to target crucial factors for PC development like PDX1 or BIRC5 (NCT03889795) [42].
In PC, M2-polarized TAM population rises significantly after gemcitabine administration,
and it has been reported how aspirin could improve the effects of gemcitabine and decrease
not only M2-polarized TAMs but also MDSCs populations [43]. MDSCs are a very hetero-
geneous immature myeloid cell population derived from the myeloid lineage that act as
a multipotent progenitor cells. They are involved in development of obesity and several
pathologies like autoimmune disease, chronic inflammation and tumorigenesis [44], and
they are characterized by the expression of CD11b and Gr-1 surface markers [45]. Sangaletti
et al. revealed how downregulation of SPARC decreased immunosuppression and reverted
invasive phenotype triggered by the presence of MDSCs [46]. Immunosuppression by
MDSCs is also driven by downregulation of JAK3, MHC class II and STAT5 that inhibit
activation of T-cells or induce their apoptosis [44]. Another study revealed that the pro-
inflammatory microenvironment that promotes MDSCs proliferation and recruitment is
produced by a cytokine cascade, which includes the release of IL-1β, IL-6, IL-13, IL-17, TNF-
α, TGF-β and VEGF [47]. Similarly, other factors such as ARG-1, COX-2, Cybb, Cytochrome
b-245, iNOS2 and PAUF are related to MDSCs activation [48]. MDSCs also impair chemo-
and radiotherapy response. In fact, high levels of proinflammatory cytokines associated
with MDSCs have been found in previously treated versus untreated patients or healthy
samples [49]. Since radiotherapy induces the release of lactate by tumor cells that lead to
activation of MDSCs, a proposed treatment strategy would imply target lactate to increase
radiotherapy response [50]. Another mechanism described recently against MDSCs is by
omega 3 administration due to its anti-inflammatory properties. Indeed, the combination
of omega 3 with gemcitabine drastically stabilizes Tregs population and decreases MDSCs
in advanced PC [51]. Other treatment approaches, like anti-CXCR2, have been described to
counteract MDSCs [52], or an anti-ENO1 that limits the invasion of MDSCs and causes the
subsequent disruption of TME interactions with tumor cells, which may improve survival
or PC patients [53].
Other studies have proposed the administration of triterpenoid to hamper the acti-
vation of MDSCs and their immunosuppressive action in PC, which lead to an increased
immune surveillance and immune response [54,55]. Therefore, diminish MDSCs popula-
tion is a potential target for the treatment of PC and increase its chemoradiosensitivity.
Molecularly, PC is characterized by inactivating mutations in TP53, RB, CDKN1A,
CDKN2A, or those associated to heritable PC such as BRCA1 and BRCA2 [56,57]. The
effect of tumor suppressor genes could be blinded by overexpression of other oncogenes
like MYC, CCNE1 or RAF [58]. Broad genomic analysis has revealed different subtypes
of PC. Bailey et al., identified four molecular subtypes of PC associated with specific
histopathological characteristics: Squamous, progenitor, immunogenic and aberrantly
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differentiated endocrine/exocrine (ADEX) [59]. The squamous molecular subtype is asso-
ciated to squamous differentiation, TP63N activation, inflammation, hypoxia, metabolic
reprogramming, dense extracellular matrix, TGF-β and WNT signaling pathway, increased
proliferation, activation of MYC, autophagy and enhanced RNA processing. Progenitor
and immunogenic subtypes share several characteristics like activation of FOXA2 and
FOXA3 networks, xenobiotic metabolism, fatty acid oxidation and mucins metabolism.
However, immunogenic subtype also involves the presence of several immune pathways
like B cell, CD4 and CD8 T cell signaling, TLR signaling, and other factors associated
with antigen presentation. ADEX is characterized by upregulation of NR5A2, RBPJL tran-
scriptional regulation pathway, exocrine differentiation, development of pancreatic β-cell,
epithelial cells differentiation and presents mutations in KRAS. Moffitt et al., proposed
other molecular subtypes based on analyses of patient prognostic and gene expression
profile of tumors (classical or basal-like tumors) and stroma (normal or activated stroma)
compared with healthy samples [60]. Collisson et al., also proposed three molecular sub-
types by a transcriptional profile analysis: Classical, which overlaps with Moffitt´s classical
subtype and exhibit high expression of molecules necessary for cell adhesion and epithe-
lial morphology; quasi-mesenchymal subtype that shows high expression levels of genes
associated to mesenchymal morphology; and exocrine-like subtype with overexpression
of genes required for digestive enzymes release [61]. These diverse molecular subtypes
exhibit several similarities with each other and highlight several opportunities for novel
therapeutic strategies and targeted drug design.
TME of PC should be different according to different molecular subtypes and their
response to chemotherapy should be different too. In the present article, we review the
four molecular subtypes of pancreatic cancer proposed by Bailey et al., and we used them
as backbone to supplement their features with other PC molecular subtypes proposed
by Moffitt et al., and Collisson et al. Furthermore, we match each molecular subtype to
a specific tumor histology and microenvironment, and how each complex network may
influence treatment response.
2. Squamous Subtype
Squamous and adenosquamous tumors represent 1–4% of all PCs, are often generated
in the head of the pancreas [62], and present the worst survival ratios even detected at early
stages [63]. These tumors frequently carry TP53 mutations and present 3p loss compared
to adenocarcinomas (Figure 1 and Table 1). Losses in 3p21.1–11.1 imply downregulation in
several anti-oncogenic genes like ROBO1, ROBO2, WNT5A, FHIT. The squamous histology
also presents upregulation of the WNT/β-Catenin signaling pathway and downregulation
of some chromatin modification factors [64]. These tumors are characterized by several
cell layers with irregular borders, protruding intercellular junctions, high eosinophilic
cytoplasm and keratin deposition, with denotes a rich and dense extracellular matrix
(Figure 1 and Table 1) [65].
The squamous molecular subtype proposed by Bailey et al., presents MYC activation
and overexpression of proteins TP63 and CD7 (TP40) as well as its target factors [59]. This
molecular subtype was associated with presence of TP53 and KDM6A mutations [59,66].
Interestingly, overexpression of TP63 in combination with TP53 mutation is able
to induce epithelial-to-mesenchymal transition to promote aggressive phenotype [67].
Squamous tumors also express integrins α6β1, α6β4 and EGF. Concerning epigenetic
modifications, this subtype exhibits an hypermethylator phenotype that downregulates
protein expression of PDX1, MNX1, GATA6 or HNF1B (Figure 1 and Table 1). However,
it presents upregulation of LOX, which is associated with metastasis development [68].
Squamous molecular subtype exhibit an hypoxic, inflamed and autophagic microenvi-
ronment that correlates with squamous histology [59]. Moreover, Moffitt et al. found a
squamous subtype characterized by overexpression associated with several components of
the extracellular matrix like laminins and keratins [60]. This matrix composition allows
an oncogenic microenvironment that fosters proliferation of PC tumor cells. This dense
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extracellular matrix generates a physical barrier for drug delivery that leads to a chemore-
sistant phenotype [69]. This rich extracellular matrix contributes to generation of hypoxic
conditions and expression of hypoxia-inducible factor 1 (HIF1) [70], and overexpression of
MUC1, VEGF and PDGF that enhance the endothelial tube formation, proliferation and
migration ability [71]. The squamous molecular subtype also presents activation of TGF-β
signaling pathway [59], and overexpression of EGFR and S100A2 [72]. These findings
support the presence and important role of PSCs in the development of squamous tumor
microenvironment since cytokines TGF-β, PDGF, Angiotensin II could bind to the PSCs
receptors and activate downstream signaling pathways such as ERK, c-Jun, P38, MAPK or
JAK-STAT to promote the activation and proliferation of PSCs. Moreover, activated PSCs
can produce and secrete to stroma a variety of growth factors through paracrine mech-
anism, to activate EGFR, PI3K-AKT, and mTOR signaling pathways, and then promote
proliferation and inhibition of apoptosis of PC cells [73,74]. One study has reported that
squamous PC cells are able to recruit neutrophils that convert PSCs into tumor-associated
fibroblasts (TAFs) that overexpress inflammatory cytokines like IL1A and CXCL1 [75].
TAFs also contribute to generate a rich tumor prone extracellular matrix by secretion of
fibroblast activating protein (FAP) that participate in angiogenesis and affect the activity of
IFN-γ and TNF-α [76].
On the other hand, the squamous molecular subtype proposed by Bailey et al. linked
with “basal-like” and “activated” stroma signatures proposed by Moffitt et al. (Figure 1 and
Table 1). The “basal-like” and “activated” stroma signatures also exhibited the worst sur-
vivals compared to “classical” and “normal” stroma subgroups, which goes in accordance
with both squamous molecular subtype of Bailey et al., and the squamous histology of
PC [60]. “Basal-like” subtype presents KRASG12D mutation, while “activated” stroma sub-
type expresses SPARC, WNT family members WNT2 and WNT5A, gelatinase B (MMP9),
stromelysin 3 (MMP11), and FAP that contribute to tumor development [60]. Further-
more, “activated” stroma subgroup is characterized by other factors like the chemokine
ligands CCL13 and CCL18, and integrin ITGAM, which are associated with the presence
of macrophages [60]. This fact suggests the important role of macrophages in the tumor
microenvironment to promote angiogenesis and chemoresistance [77]. In this sense, it
has been described how TAMs enable chemoresistance to gemcitabine and nab-paclitaxel
by expression of insulin growth factor (IGF) that activates IGF-1 receptors [78]. It has
been reported that PSCs also promote gemcitabine resistance mediated by secretion of
deoxycytidine that modulate nucleoside transporters [79]. Moreover, PSCs reduce the sensi-
tivity of PC cells to radiotherapy by regulation of epithelial-to-mesenchymal transition and
increasing cancer stem cell markers [80]. Furthermore, these authors provide a rationale
for the use of an anti-TGF-β neutralizing antibody to inhibit epithelial-to-mesenchymal
transition and cancer stem cells to sensitize cells to radiation and reduce tumors [80].
Other cell population like tumor associated fibroblasts can secrete proinflammatory factors
like IL-6, which activates STAT3, and secrete CXCL12 that inhibit T-cells infiltration in
tumors [81]. In addition, CXCL12 in combination with anti-PD-L1 immunotherapy has
shown a synergic anti-tumor effect and is considered a potential target for those PCs with
high FAP expression [82].
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Figure 1. Squamous molecular profile and microenvironment. (a) Squamous subtype is associated 
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proposed by Moffitt et al. Green boxes contain upregulated significant factors and activated path-
ways associated to squamous molecular subtype. Red boxes contain downregulated significant 
factors (up) and most common mutations found in squamous molecular subtype (down). Percent-
age of each subcellular population has been obtained from Peng et al., [86]. Abbreviations: TAM: 
Tumor-associated macrophage; CAF: Cancer-associated fibroblast; PSC: Pancreatic stellate cell. 
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transcriptional networks that exhibit high expression of the proteins HES1, HNF1A, 
HNF1B, HNF4A, HNF4G, FOXA2, FOXA3, LAMA1, MNX1 and EP300 (Figure 2 and Ta-
ble 1) [59]. These transcription factors are considered crucial for determination and devel-
opment of the pancreatic endoderm. While the squamous subtype presented downregu-
lation of PDX1, which is also critical for pancreatic development, the progenitor subtype 
overexpress PDX1 (Figure 2 and Table 1) [88]. Moreover, progenitor molecular subtype 
expresses multiple genes necessary for the metabolism of mucins, fatty acids, steroid hor-
mones, and also involves drug metabolism. Indeed, progenitor molecular subtype over-
expresses MUC5AC and MUC1 (Figure 2 and Table 1) [59]. Interestingly, both progenitor 
and immunogenic molecular subtypes share the same histology derived from premalig-
nant lesions like mucinous non-cystic adenocarcinomas and intraductal papillary mucin-
ous neoplasms (IPMN), characterized by a high mucin production (Figure 2 and Table 1) 
[106], different epithelial-to-mesenchymal transition markers [107], and immunohisto-
chemical staining of CDX2 [89,90]. 
The immunogenic molecular subtype also presents many other similarities in the 
gene expression profile with the progenitor subtype; however, immunogenic subtype ex-
hibit a significantly higher immune infiltrate [59]. Gene expression analysis identified up-
regulation in those genes associated with nine different populations of immune cells [108], 
being the most significant those involved with B and T cells infiltration (CD4, CD8, CD25, 
FOXP3) (Figure 2 and Table 1). Furthermore, immunogenic subtype presents activation of 
CTLA4 and PD1, which suggests that this molecular subtype could be feasible treated 
with immunecheckpoints inhibitors [59]. In contrast, the pancreatic progenitor subtype 
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macrophage; CAF: Cancer-associated fibroblast; PSC: Pancreatic stellate cell.





Subpopulations Molecular Profile of Cellular Subpopulation
Expression of Cytokines,
Chemokines and Receptors Clinical Significance
Squamous
Tumor cells
TP53 and KDM6A mutations [59,66]; KRAS-G12D- mutation
[60]; overexpression of LOX [68]; upregulation of TP63, TP40
and IDO1 [59]; activation of WNT/β-Catenin pathway [64],
MYC activation [59]; overexpre sion of HIF1 [70], MUC1
and PDGF [71], ROBO1, ROBO2, WNT5A, FHIT [64];
downregulation of PDX1, MNX1, GATA6 and HNF1B [59];
Laminins and keratins [60];







a gressive pheno pe
[83,84]
Stellate cell
Activation of ERK, c-Jun, P38, MAPK, JAK-STAT, PI3K-AKT,
mTOR and cancer stem cell markers [73,74]; overexpression
of RGS5, ACTA2, PDGFRB, SOD3, NOTCH3, COL18A1,
COL4A1, NDUFA4L2, COL4A2, SEPT4, COL14A1 and
SPARC [86]
Integrins α6β1, α6β4 and






Endothelial cells Overexpression of COL15A1, RAMP2, CDH5, SPARCL1,NOTCH4, SMAD9 and JAM2 [86] VEGF [71] Angiogenesis [87]
Macrophages Overexpression of AIF1, APOC1, APOE, C1QB, C1QA,C1QC, NCF2 and CCL2 [86]




CD68, CD74, FTH1, FTL,






SFRP2, LUM, COL1A1, COL1A2, DCN, COL3A1, MMP11,
COL6A3, COL10A1, COL5A2, SPARC, COL6A2, COL5A1,
COL6A1, COL8A1, COL12A1, MMP14, FGF7, FAP [86]
EGFR a d S100A2 [72]; IL1A
and CXCL1 [75]; IFN-γ,










Subpopulations Molecular Profile of Cellular Subpopulation
Expression of Cytokines,
Chemokines and Receptors Clinical Significance
Progenitor
Tumor cells
KRAS-G12V- mutation [60]; TGFBR2 mutation [59];
overexpression of MUC5AC and MUC1 [59]; upregulation
of HES1, HNF1A, HNF1B, HNF4A, HNF4G, FOXA2,
FOXA3, LAMA1, MNX1 and EP300 [59]; overexpression of
PDX1 [88], GATA6 [60] and CDX2 [89,90]; downregulation
of IDO1 [59], LOX and S100A [59]
High mucin production [60];
low levels of EGFR, CTLA4,








Ductal cells type 2 Overexpression of SOX9 [86]
CEACAM1, CEACAM5,
CEACAM6, EPCAM, IL18,















B cells Upregulation of LIMD2, IRF8, BANK1 and RAC2 [86]
CD19, CD20, CD37, CD52,
CD53, CD74, CD79A, CD79B,




T cells Upregulation of FOXP3 [59]; Upregulation of RAC2 [86]
CD4, CD8, CD25, CTLA4 and
PD1 [59]; CCL5, CD2, CD3E,
CD3D, CD3G, CD7, CD45,
CD52, CD69, CXCR4, IL2RG,
IL7R, IL32, KLRB1, LTB [86]
Promote tumor
immunosuppression




Macrophages Upregulation of AIF1, APOC1, APOE, C1QB, C1QA, C1QC,FTH1, NCF2 [86]
IL10 and TGF-β [97]; CSF1R,
TLR4, TLR7, TLR8, PD-L2
[59]; CD14, CD53, CD68,
CD74, CCL2, HLA-DRA,
HLA-DPA1, HLA-DPB1, IL8,




Presence of mutations in: FAT1, FAT3, and FAT4 (57%),
BRCA2 (42%), SMAD4 (26%), JAK1 (17%), RB1 (13%), TP53
(13%), CTNNB1 (11%), APC (9%), ARID1A (9%), GNAS (9%),
MLL3 (9%), PTEN (9%), RNF43 (4%) and MEN1 (4%);
however, KRAS mutations are scarce [98,99]; upregulation of





Acinar cells Expression of BCL-10 [65]
IL32, PRSS1, REG1A, REG1B,





Overexpression of ACTA2, DES and VIM [60,102];
COL18A1, COL4A1, COL4A2, COL14A1, NDUFA4L2,
NOTCH3, RGS5, SEPT4, SOD3 and SPARC [86]









Endocrine cells Overexpression of INS, NEUROD1, NKX2-2, MAFA [59],and ABCC8 [86]
CHGA, CHGB, IAPP,






Unfortunately, Bailey et al., support that squamous molecular subtype exhibits the
highest expression of PD-L1, PD-L2 and IDO1 [59], thus, they sustain that these tumors are
not good candidates for immunotherapy administration [83,84].
However, the combination of IDO1 inhibitor and anti-PD-1/PD-L1 treatment could
achieve promising results and become a potential strategy to induce intratumoral T-cell
infiltration [85]. In the light of the foregoing, the microenvironment of the squamous
molecular subtype presents a complex interaction between different cell populations and
extracellular components to confer chemoresistance of PC.
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3. Progenitor and Immunogenic Subtypes
The progenitor molecular subtype proposed by Bailey et al. presents activation on
transcriptional networks that exhibit high expression of the proteins HES1, HNF1A, HNF1B,
HNF4A, HNF4G, FOXA2, FOXA3, LAMA1, MNX1 and EP300 (Figure 2 and Table 1) [59].
These transcription factors are considered crucial for determination and development of the
pancreatic endoderm. While the squamous subtype presented downregulation of PDX1,
which is also critical for pancreatic development, the progenitor subtype overexpress PDX1
(Figure 2 and Table 1) [88]. Moreover, progenitor molecular subtype expresses multiple
genes necessary for the metabolism of mucins, fatty acids, steroid hormones, and also
involves drug metabolism. Indeed, progenitor molecular subtype overexpresses MUC5AC
and MUC1 (Figure 2 and Table 1) [59]. Interestingly, both progenitor and immunogenic
molecular subtypes share the same histology derived from premalignant lesions like
mucinous non-cystic adenocarcinomas and intraductal papillary mucinous neoplasms
(IPMN), characterized by a high mucin production (Figure 2 and Table 1) [106], different
epithelial-to-mesenchymal transition markers [107], and immunohistochemical staining of
CDX2 [89,90].
The immunogenic molecular subtype also presents many other similarities in the gene
expression profile with the progenitor subtype; however, immunogenic subtype exhibit
a significantly higher immune infiltrate [59]. Gene expression analysis identified upreg-
ulation in those genes associated with nine different populations of immune cells [108],
being the most significant those involved with B and T cells infiltration (CD4, CD8, CD25,
FOXP3) (Figure 2 and Table 1). Furthermore, immunogenic subtype presents activation
of CTLA4 and PD1, which suggests that this molecular subtype could be feasible treated
with immunecheckpoints inhibitors [59]. In contrast, the pancreatic progenitor subtype
presents the lowest levels of CTLA4, PD-L1, PD-L2, and IDO1 [59]. The immunogenic
subtype also has enrichment in genes for Toll-like receptors that play a key role in the innate
immune system. These genes include TLR4, TLR7, TLR8, PD-L2 and CSF1R (Figure 2 and
Table 1) [59]. These receptors usually are expressed on sentinel cells such as macrophages
and dendritic cells, which reveal the strong link between the immunogenic molecular
subtype with the presence of immune cell population in the TME (Figure 2 and Table 1).
In this sense, TAMs present in PC, especially those M2-type macrophages can promote
neovasculature formation to feed tumor cells and induce chemoresistance, proliferation,
invasion and metastasis of PC tumor cells [77]. TAMs could be recruited to neoplasic foci
by cytokines and vascular endothelial growth factors (VEGF). Once there, TAMs promote
proliferation of PC cells through the release of growth factors like Il10 or TGF-β [97]. In
addition, the presence of TAMs in the TME is associated with chemoresistance [78].
On the other hand, the immunogenic molecular subtype of PC present inflammation,
caused by abundant Tregs infiltration and high expression of cytotoxic T lymphocyte-
associated protein 4 (CTLA-4). These factors promote tumor immunosuppression through
the inhibition of the killing ability of effector cells [95]. The presence of CD8+ T cells
in immunogenic subtype can decrease the capability of anti-tumor immune cells due
to the ability of CD8+T cells to express FAS-ligand and secrete perforin and granzymes
with cytolytic effect [96]. Despite the immunosuppressive skills of immunogenic subtype,
patients with this kind of tumor present the best outcome out of the four molecular
subtypes [59].
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Interestingly, both progenitor and immunogenic subtypes correlate with “classical”
tumor subtype proposed by Moffitt et al., which also share the expression of extracellular
mucin in more than 10% (Figure 2 and Table 1) [60]. Similarly to immunogenic molec-
ular subtype, “classical” tumors present better outcome compared to those “basal-like”
tumors [60]. Remarkably, progenitor and immunogenic molecular subtypes by Bailey et al.
and “classical” tumor subtype by Moffitt et al., correlate with the same gene expression sig-
nature of “classical” tumor subtype proposed by Collisson et al. (Figure 2 and Table 1) [109].
This fact supports the presence of the G12V variant of KRAS mutation that is associated
with the “classical” subtype [60]. “Classical” molecular subtype also presents enrichment
in genes associated with GATA6 overexpression responsible for promoting epithelial cell
differentiation [60]. However, other authors propose the loss of GATA6 expression in
tumors confers a shorter survival and they have a poor response to adjuvant treatment
based on 5-fluorouracil (5-FU)/leucovorin [91]. In this sense, “classical” molecular subtype
tumors also exhibit poor response to platinum based therapy [60]. Therefore, the adju-
vant treatment used for the management of immunogenic/progenitor/classical molecular
subtype tumors would be more aggressive to overcome the chemoresistance. For this, im-
munotherapy has arisen as one of the most effective anti-tumor treatments. PC overexpress
important factors for targeted therapies, such as MUC-1, CEA, PSC, VEGF, MSLN and mu-
tation KRAS [110]. However, the most important targets for immunotherapy currently are
PD-1, PD-L1 and CTLA-4. In animal models, anti-PD-1 or anti-PD-L1 treatment boosted
infiltration of CD8+ T cells in the tumor and enhanced efficacy of immunocheckpoint
inhibitors.
Regretfully, immunotherapy against PC has presented no benefit in clinical trials
so far [111,112]. Currently, the failure of anti-PD-1/anti-PD-L1 based therapy is mainly
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attributed to the lack of T-cell infiltration in the TME of PC. Therefore, the immunogenic
molecular subtype that presents elevated genes for B- and T-cell infiltration is a potential
responder for immunotherapy. Other type of immunotherapy based on CAR-T cells has
obtained promising results. Some clinical trials have focused on modified CAR-T cells
able to target MUC1 or Mesothelin (MSLN) [113]. Although MUC1 is overexpressed in
approximately 85% of PC, those tumors present overexpression of IDO1, COX1/2, and
Gal-9 that conferred resistance to these anti-MUC1 CAR-T cells [114]. However, the use
of inhibitors of IDO1, COX1/2, and Gal-9 overcame this resistance in combination with
anti-MUC1 CAR-T cells [114]. In this concern, a phase I/II trial has been designed with
resectable PC patients´ T cells modified to allow identification and kill of MUC1 positive
tumor cells (NCT02587689). CAR-T cells could be engineered to target other antigens such
as Mesothelin, and they have achieved encouraging results in solid malignancies [115],
which has established the bases for a subsequent clinical trial with anti-MSLN CAR-T cells
(NCT04203459). Although CAR-T cell therapy has achieved favorable results, it is crucial
to evaluate the potential side effects on T-cell exhaustion.
The ADEX molecular subtype by Bailey et al., is defined by the orchestrated expres-
sion of factors necessary for the exocrine and endocrine pancreatic cell-fate determination.
ADEX presents upregulation in transcription factors involved in healing and regenera-
tion after pancreatitis events such as RBPJL, NR5A2, MIST1 and their associated down-
stream cascade factors (Figure 3 and Table 1) [100,101]. This molecular subtype exhibits
an expression profile associated with extremely rare acinar histopathology (Figure 3 and
Table 1) [59,63]. Macroscopically, this histology shows large tumors, frequently presented
in encapsulated form and well circumscribed. It also presents cystic evolution, necrosis,
and upper digestive hemorrhage [116]. In clinical practice, diagnosis of acinar carcinomas
is performed by immunohistochemical evaluation of pancreatic enzymes like trypsin and
chymotrypsin that are produced in the rough endoplasmic reticulum of acinar cells. It also
presents high specificity for BCL-10 immunostaining [65]. Furthermore, somatic mutational
index of acinar subtype is higher than adenocarcinoma being the most frequent mutations
in the following genes: FAT1, FAT3, and FAT4 (57%), BRCA2 (42%), SMAD4 (26%), JAK1
(17%), RB1 (13%), TP53 (13%), CTNNB1 (11%), APC (9%), ARID1A (9%), GNAS (9%), MLL3
(9%), PTEN (9%), RNF43 (4%) and MEN1 (4%); however, KRAS mutations are not often
observed in acinar subtype (Figure 3 and Table 1) [98,99]. In this sense, Bailey et al. found
in ADEX molecular subtype high expression levels of INS, NEUROD1, NKX2-2 and MAFA,
which are associated with endocrine differentiation and sudden occurrence of diabetes
type MODY (Figure 3 and Table 1).
Importantly, most PC-derived cell lines present enrichment in genes found in ADEX
molecular subtype like AMY2B, CEL, INS, PRSS1 and PRSS3 [59].
ADEX molecular subtype proposed by Bailey et al., matches perfectly with “exocrine-
like” subtype proposed by Collisson et al., which shows relatively high expression of
tumor cell-derived digestive enzymes like ELA3A and CFTR, which controls Cl− and Na+
ions, and water flux (Figure 3 and Table 1) [61]. In addition, ADEX molecular subtype
correlates with “normal stroma” subtype proposed by Moffitt et al., which exhibit longer
survival rates (Figure 3 and Table 1) [60]. “Normal stroma” is also distinguished by high
expression levels of PSCs markers: Smooth muscle actin (ACTA2), Desmin (DES) and
Vimentin (VIM) [60,102]. This fact highlights the importance of the PSCs population in the
ADEX microenvironment. PSCs role go in accordance with ADEX origin, since they present
expression markers of stem and progenitor cells needed to maintain differentiation and
regeneration of pancreas [117]. Indeed, PSCs are necessary to trigger desmoplastic reaction
by the synthesize of large amounts of extracellular matrix proteins, such as collagens, and
amplify endostatin production of cancer cells that contributes to an hypoxic milieu [103,118].
Moverover, PSCs produce VEGF to increase endothelial cell growth in the peritumoral
stroma [103]. All the above supports the role of PSCs in induction of fibrosis [119], that
impairs drug delivery, stimulates epithelial-to-mesenchymal transition, and increases
genetic instability leading to a more chemoresistant tumor [104]. Furthermore, PSCs play a
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crucial role in islet cell dysfunction since PSCs decrease insulin expression and an increased
apoptosis of pancreatic β-cells that connects to initiation of diabetes [105]. One study
supported that PC cells cultured with extracellular matrix proteins produced by PSCs were
able to develop resistance to 5-FU, cisplatin and doxorubicin [120]. As above mentioned,
the presence of PSCs in ADEX molecular subtype could imply resistance to gemcitabine [79]
and a reduced sensitivity to radiotherapy [80].
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4. Conclusions and Future Perspectives
The match between molecular features at genomic, epigenomic and expression levels
combined with the biological behavior of PC is bringing new therapeutic strategies for the
clinical management of these patients. In additi n, the study of the TME could ex lain
chemoresistance of PC previously attributed only to tumor cells. The TME and especially
the role of its immune cell population in tumor initiation, development and immune
evasion is changing the paradigm of PC diagnosis and treatment approach with the
identification of new molecular subtypes (Table 2).
Table 2. On-going clinical trials that include different subtypes of pancreatic cancer.
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enrollment for comprehensive
molecular characterization
Cancers 2021, 13, 322 12 of 18
Table 2. Cont.
Clinical Trial Study Type Treatment Patients Aim
NCT04246710 ObservationalProspective Not specified
Resectable, borderline resectable,
locally advanced, metastatic and
recurrent pancreatic cancer
Molecular characterization and
























(MSI-H) or mismatch repair-deficient
(dMMR) pancreatic cancer that have
progressed following prior treatment
and have no satisfactory alternative
treatment options.
Assess of tumor PD-L1/dMMR




samples, and the prospective
correlation of MMR status and
PD-L1 expression with overall
survival and progression-free
survival of PDAC patients.
NCT04436679 ObservationalRetrospective None
Excreto-pancreatic adenocarcinoma




characteristics of the stroma,
tumor budding and mucin




NCT03840460 ObservationalProspective Not specified
Early and advanced pancreatic
adenocarcinoma, precursor lesions or
pancreatic neuroendocrine tumors.
Study the molecular profile of
pancreatic lesions and their
microenvironment at various
stages to predict treatment







Although treatment strategies based on immunocheckpoint inhibitors have shown
disappointing results, new studies are ongoing with novel drug design to improve patient
response, and to avoid tumor immune evasion. In this concern, a randomized clinical trial
(NCT02030860) aimed to evaluate paricalcitol that target vitamin D metabolism in the TME
in combination with gemcitabine plus nab-paclitaxel in the neoadjuvant scenario for re-
sectable PC patients. Another phase I/II clinical trial is designed to evaluate the safety and
tolerability of the microenvironment modifier drug, L-DOS47, in combination with dox-
orubicin. The L-DOS47 is reported to neutralize the acid extracellular matrix that protects
the tumor (NCT04203641) [121]. Recently, other treatments like GVAX or CRS-207 have
appeared with promising results against PC [122]. GVAX is a vaccine based on granulocyte-
macrophage colony-stimulating factor that inhibits Tregs and induces T cells; while CRS-207
is a vaccine based on live-attenuated Listeria monocytogenes–expressing mesothelin that has
been described to induce innate and adaptive immune response against tumor cells and
has achieved longer survivals of PC patients (NCT03161379; NCT02451982) [122]. Other
drugs are based on nucleic acid, this is the case of olaptesed pegol a L-RNA Spiegelmer
that exhibits a high affinity against CXCL12, a factor previously described responsible for
TAMs recruitment (NCT03168139) [123]. These new treatment approaches highlight the
importance of targeting not only tumor cells but also TME. Although translational research
and drug design are working synergistically to improve outcome of PC patients, clinical
research must not ignore that patients might be stratified not only based on performance
Cancers 2021, 13, 322 13 of 18
status of patients and/or the molecular characteristics of tumors, but also according to
their TME features to obtain better treatment responses and longer survivals.
Author Contributions: Conceptualization, J.M.-U. and J.G.-F. writing—original draft preparation,
J.M.-U. figures and tables, M.M.-G.; writing—review and editing, M.M.-G. and J.M.-U. visualization,
M.M.-G. supervision, J.G.-F. funding acquisition, J.G.-F. All authors have read and agreed to the
published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: We especially thank oncologist Aberto Orta-Ruiz (MD, PhD) from the Medi-
cal Oncology Department (Fundacion Jimenez Diaz University Hospital) for his appreciated revi-
sion, suggestions and criticism for the present review article. All figures have been designed with
BioRender.com.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting Cancer Incidence and Deaths
to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014, 74, 2913–2921.
[CrossRef] [PubMed]
2. Tamm, E.P.; Bhosale, P.R.; Vikram, R.; de Almeida Marcal, L.P.; Balachandran, A. Imaging of Pancreatic Ductal Adenocarcinoma:
State of the Art. World J. Radiol. 2013, 5, 98–105. [CrossRef] [PubMed]
3. Kelsen, D.P.; Portenoy, R.; Thaler, H.; Tao, Y.; Brennan, M. Pain as a Predictor of Outcome in Patients with Operable Pancreatic
Carcinoma. Surgery 1997, 122, 53–59. [CrossRef]
4. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [CrossRef] [PubMed]
5. Duffy, M.J.; Sturgeon, C.; Lamerz, R.; Haglund, C.; Holubec, V.L.; Klapdor, R.; Nicolini, A.; Topolcan, O.; Heinemann, V. Tumor
Markers in Pancreatic Cancer: A European Group on Tumor Markers (EGTM) Status Report. Ann. Oncol. 2010, 21, 441–447.
[CrossRef] [PubMed]
6. Kim, J.-E.; Lee, K.T.; Lee, J.K.; Paik, S.W.; Rhee, J.C.; Choi, K.W. Clinical Usefulness of Carbohydrate Antigen 19-9 as a Screening
Test for Pancreatic Cancer in an Asymptomatic Population. J. Gastroenterol. Hepatol. 2004, 19, 182–186. [CrossRef]
7. Ferri, M.J.; Saez, M.; Figueras, J.; Fort, E.; Sabat, M.; López-Ben, S.; de Llorens, R.; Aleixandre, R.N.; Peracaula, R. Improved
Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the
Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology. PLoS ONE 2016, 11,
e0147214. [CrossRef]
8. Blackford, A.; Parmigiani, G.; Kensler, T.W.; Wolfgang, C.; Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.-H.; Leary, R.J.; Eshleman,
J.R.; et al. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Res. 2009, 69, 3681–3688. [CrossRef]
9. Bosetti, C.; Lucenteforte, E.; Silverman, D.T.; Petersen, G.; Bracci, P.M.; Ji, B.T.; Negri, E.; Li, D.; Risch, H.A.; Olson, S.H.; et al.
Cigarette Smoking and Pancreatic Cancer: An Analysis from the International Pancreatic Cancer Case-Control Consortium
(Panc4). Ann. Oncol. 2012, 23, 1880–1888. [CrossRef]
10. Lowenfels, A.B.; Maisonneuve, P.; DiMagno, E.P.; Elitsur, Y.; Gates, L.K.; Perrault, J.; Whitcomb, D.C. Hereditary Pancreatitis
and the Risk of Pancreatic Cancer. International Hereditary Pancreatitis Study Group. J. Natl. Cancer Inst. 1997, 89, 442–446.
[CrossRef]
11. Chari, S.T.; Leibson, C.L.; Rabe, K.G.; Timmons, L.J.; Ransom, J.; de Andrade, M.; Petersen, G.M. Pancreatic Cancer-Associated
Diabetes Mellitus: Prevalence and Temporal Association with Diagnosis of Cancer. Gastroenterology 2008, 134, 95–101. [CrossRef]
[PubMed]
12. Chen, X.-Z.; Wang, R.; Chen, H.-N.; Hu, J.-K. Cytotoxin-Associated Gene A-Negative Strains of Helicobacter Pylori as a Potential
Risk Factor of Pancreatic Cancer: A Meta-Analysis Based on Nested Case-Control Studies. Pancreas 2015, 44, 1340–1344. [CrossRef]
[PubMed]
13. Neoptolemos, J.P.; Urrutia, R.; Abbruzzese, J.L.; Büchler, M.W. Pancreatic Cancer; Springer: Berlin/Heidelberg, Germany, 2018;
ISBN 9781493971930.
14. Oettle, H.; Post, S.; Neuhaus, P.; Gellert, K.; Langrehr, J.; Ridwelski, K.; Schramm, H.; Fahlke, J.; Zuelke, C.; Burkart, C.; et al.
Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients Undergoing Curative-Intent Resection of Pancreatic
Cancer: A Randomized Controlled Trial. J. Am. Med. Assoc. 2007, 297, 267–277. [CrossRef] [PubMed]
15. Neoptolemos, J.P.; Stocken, D.D.; Bassi, C.; Ghaneh, P.; Cunningham, D.; Goldstein, D.; Padbury, R.; Moore, M.J.; Gallinger, S.;
Mariette, C.; et al. Adjuvant Chemotherapy with Fluorouracil plus Folinic Acid vs. Gemcitabine Following Pancreatic Cancer
Resection: A Randomized Controlled Trial. JAMA J. Am. Med. Assoc. 2010, 304, 1073–1081. [CrossRef] [PubMed]
16. Neoptolemos, J.P.; Palmer, D.; Ghaneh, P.; Valle, J.W.; Cunningham, D.; Wadsley, J.; Meyer, T.; Anthoney, A.; Glimelius, B.; Falk,
S.; et al. ESPAC-4: A Multicenter, International, Open-Label Randomized Controlled Phase III Trial of Adjuvant Combination
Cancers 2021, 13, 322 14 of 18
Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP) versus Monotherapy Gemcitabine in Patients with Resected
Pancreatic Ductal Adenocarcin. J. Clin. Oncol. 2016, 34. [CrossRef]
17. Vera, R.; Dotor, E.; Feliu, J.; González, E.; Laquente, B.; Macarulla, T.; Martínez, E.; Maurel, J.; Salgado, M.; Manzano, J.L. SEOM
Clinical Guideline for the Treatment of Pancreatic Cancer. Clin. Transl. Oncol. 2016, 18, 1172–1178. [CrossRef]
18. Mukherjee, S.; Hurt, C.N.; Bridgewater, J.; Falk, S.; Cummins, S.; Wasan, H.; Crosby, T.; Jephcott, C.; Roy, R.; Radhakrishna, G.;
et al. Gemcitabine-Based or Capecitabine-Based Chemoradiotherapy for Locally Advanced Pancreatic Cancer (SCALOP): A
Multicentre, Randomised, Phase 2 Trial. Lancet Oncol. 2013, 14, 317–326. [CrossRef]
19. Hammel, P.; Huguet, F.; Van Laethem, J.-L.; Goldstein, D.; Glimelius, B.; Artru, P.; Borbath, I.; Bouche, O.; Shannon, J.; André, T.;
et al. Comparison of Chemoradiotherapy (CRT) and Chemotherapy (CT) in Patients with a Locally Advanced Pancreatic Cancer
(LAPC) Controlled after 4 Months of Gemcitabine with or without Erlotinib: Final Results of the International Phase III LAP 07
Study. J. Clin. Oncol. 2013, 31. [CrossRef]
20. Zeng, S.; Pöttler, M.; Lan, B.; Grützmann, R.; Pilarsky, C.; Yang, H. Chemoresistance in Pancreatic Cancer. Int. J. Mol. Sci. 2019, 20,
4504. [CrossRef]
21. Ioannides, C.G.; Whiteside, T.L. T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of Cancer.
Clin. Immunol. Immunopathol. 1993, 66, 91–106. [CrossRef]
22. Apte, M.V.; Xu, Z.; Pothula, S.; Goldstein, D.; Pirola, R.C.; Wilson, J.S. Pancreatic Cancer: The Microenvironment Needs Attention
Too! Pancreatology 2015, 15, S32–S38. [CrossRef] [PubMed]
23. Chang, J.H.; Jiang, Y.; Pillarisetty, V.G. Role of Immune Cells in Pancreatic Cancer from Bench to Clinical Application: An Updated
Review. Medicine 2016, 95, e5541. [CrossRef] [PubMed]
24. Roberts, N.J.; Norris, A.L.; Petersen, G.M.; Bondy, M.L.; Brand, R.; Gallinger, S.; Kurtz, R.C.; Olson, S.H.; Rustgi, A.K.; Schwartz,
A.G.; et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov. 2016, 6,
166–175. [CrossRef] [PubMed]
25. Pothula, S.P.; Pirola, R.C.; Wilson, J.S.; Apte, M.V. Pancreatic Stellate Cells: Aiding and Abetting Pancreatic Cancer Progression.
Pancreatology 2020, 20, 409–418. [CrossRef] [PubMed]
26. Xue, R.; Jia, K.; Wang, J.; Yang, L.; Wang, Y.; Gao, L.; Hao, J. A Rising Star in Pancreatic Diseases: Pancreatic Stellate Cells. Front.
Physiol. 2018, 9, 754. [CrossRef]
27. Che, M.; Kweon, S.-M.; Teo, J.-L.; Yuan, Y.-C.; Melstrom, L.G.; Waldron, R.T.; Lugea, A.; Urrutia, R.A.; Pandol, S.J.; Lai, K.K.Y.
Targeting the CBP/β-Catenin Interaction to Suppress Activation of Cancer-Promoting Pancreatic Stellate Cells. Cancers 2020, 12,
1476. [CrossRef]
28. Ikenaga, N.; Ohuchida, K.; Mizumoto, K.; Cui, L.; Kayashima, T.; Morimatsu, K.; Moriyama, T.; Nakata, K.; Fujita, H.; Tanaka, M.
CD10+ Pancreatic Stellate Cells Enhance the Progression of Pancreatic Cancer. Gastroenterology 2010, 139, 1041–1051. [CrossRef]
29. Zha, M.; Xu, W.; Zhai, Q.; Li, F.; Chen, B.; Sun, Z. High Glucose Aggravates the Detrimental Effects of Pancreatic Stellate Cells on
Beta-Cell Function. Int. J. Endocrinol. 2014, 2014, 165612. [CrossRef]
30. Li, F.-F.; Chen, B.-J.; Li, W.; Li, L.; Zha, M.; Zhou, S.; Bachem, M.G.; Sun, Z.-L. Islet Stellate Cells Isolated from Fibrotic Islet of
Goto-Kakizaki Rats Affect Biological Behavior of Beta-Cell. J. Diabetes Res. 2016, 2016, 6924593. [CrossRef]
31. Lee, E.; Ryu, G.R.; Ko, S.-H.; Ahn, Y.-B.; Song, K.-H. A Role of Pancreatic Stellate Cells in Islet Fibrosis and β-Cell Dysfunction in
Type 2 Diabetes Mellitus. Biochem. Biophys. Res. Commun. 2017, 485, 328–334. [CrossRef]
32. Jang, J.-E.; Hajdu, C.H.; Liot, C.; Miller, G.; Dustin, M.L.; Bar-Sagi, D. Crosstalk between Regulatory T Cells and Tumor-Associated
Dendritic Cells Negates Anti-Tumor Immunity in Pancreatic Cancer. Cell Rep. 2017, 20, 558–571. [CrossRef] [PubMed]
33. Aykut, B.; Chen, R.; Miller, G. Regulatory T Cells Keep Pancreatic Cancer at Bay. Cancer Discov. 2020, 10, 345–347. [CrossRef]
[PubMed]
34. Shevchenko, I.; Karakhanova, S.; Soltek, S.; Link, J.; Bayry, J.; Werner, J.; Umansky, V.; Bazhin, A.V. Low-Dose Gemcitabine
Depletes Regulatory T Cells and Improves Survival in the Orthotopic Panc02 Model of Pancreatic Cancer. Int. J. Cancer 2013, 133,
98–107. [CrossRef] [PubMed]
35. Cheng, H.; Luo, G.; Lu, Y.; Jin, K.; Guo, M.; Xu, J.; Long, J.; Liu, L.; Yu, X.; Liu, C. The Combination of Systemic Inflammation-Based
Marker NLR and Circulating Regulatory T Cells Predicts the Prognosis of Resectable Pancreatic Cancer Patients. Pancreatology
2016, 16, 1080–1084. [CrossRef]
36. Liu, C.-Y.; Xu, J.-Y.; Shi, X.-Y.; Huang, W.; Ruan, T.-Y.; Xie, P.; Ding, J.-L. M2-Polarized Tumor-Associated Macrophages Promoted
Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells, Partially through TLR4/IL-10 Signaling Pathway. Lab. Invest. 2013,
93, 844–854. [CrossRef]
37. Meng, F.; Li, C.; Li, W.; Gao, Z.; Guo, K.; Song, S. Interaction between Pancreatic Cancer Cells and Tumor-Associated Macrophages
Promotes the Invasion of Pancreatic Cancer Cells and the Differentiation and Migration of Macrophages. IUBMB Life 2014, 66,
835–846. [CrossRef]
38. Malmberg, K.-J. Effective Immunotherapy against Cancer: A Question of Overcoming Immune Suppression and Immune Escape?
Cancer Immunol. Immunother. 2004, 53, 879–892. [CrossRef]
39. Shen, Z.; Seppänen, H.; Kauttu, T.; Vainionpää, S.; Ye, Y.; Wang, S.; Mustonen, H.; Puolakkainen, P. Vasohibin-1 Expression
Is Regulated by Transforming Growth Factor-β/Bone Morphogenic Protein Signaling Pathway Between Tumor-Associated
Macrophages and Pancreatic Cancer Cells. J. Interferon. Cytokine Res. 2013, 33, 428–433. [CrossRef]
Cancers 2021, 13, 322 15 of 18
40. Hu, H.; Hang, J.-J.; Han, T.; Zhuo, M.; Jiao, F.; Wang, L.-W. The M2 Phenotype of Tumor-Associated Macrophages in the Stroma
Confers a Poor Prognosis in Pancreatic Cancer. Tumour Biol. 2016, 37, 8657–8664. [CrossRef]
41. Incio, J.; Suboj, P.; Chin, S.M.; Vardam-Kaur, T.; Liu, H.; Hato, T.; Babykutty, S.; Chen, I.; Deshpande, V.; Jain, R.K.; et al. Metformin
Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PLoS ONE
2015, 10, e0141392. [CrossRef]
42. Liu, S.-H.; Yu, J.; Creeden, J.F.; Sutton, J.M.; Markowiak, S.; Sanchez, R.; Nemunaitis, J.; Kalinoski, A.; Zhang, J.-T.; Damoiseaux,
R.; et al. Repurposing Metformin, Simvastatin and Digoxin as a Combination for Targeted Therapy for Pancreatic Ductal
Adenocarcinoma. Cancer Lett. 2020, 491, 97–107. [CrossRef] [PubMed]
43. Liu, Q.; Li, Y.; Niu, Z.; Zong, Y.; Wang, M.; Yao, L.; Lu, Z.; Liao, Q.; Zhao, Y. Atorvastatin (Lipitor) Attenuates the Effects of
Aspirin on Pancreatic Cancerogenesis and the Chemotherapeutic Efficacy of Gemcitabine on Pancreatic Cancer by Promoting M2
Polarized Tumor Associated Macrophages. J. Exp. Clin. Cancer Res. 2016, 35, 33. [CrossRef] [PubMed]
44. Gabrilovich, D.I.; Nagaraj, S. Myeloid-Derived Suppressor Cells as Regulators of the Immune System. Nat. Rev. Immunol. 2009, 9,
162–174. [CrossRef] [PubMed]
45. Talmadge, J.E.; Gabrilovich, D.I. History of Myeloid-Derived Suppressor Cells. Nat. Rev. Cancer 2013, 13, 739–752. [CrossRef]
[PubMed]
46. Sangaletti, S.; Talarico, G.; Chiodoni, C.; Cappetti, B.; Botti, L.; Portararo, P.; Gulino, A.; Consonni, F.M.; Sica, A.; Randon, G.; et al.
SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. Front. Immunol. 2019, 10. [CrossRef]
[PubMed]
47. Karakhanova, S.; Link, J.; Heinrich, M.; Shevchenko, I.; Yang, Y.; Hassenpflug, M.; Bunge, H.; von Ahn, K.; Brecht, R.; Mathes,
A.; et al. Characterization of Myeloid Leukocytes and Soluble Mediators in Pancreatic Cancer: Importance of Myeloid-Derived
Suppressor Cells. Oncoimmunology 2015, 4, e998519. [CrossRef] [PubMed]
48. Song, J.; Lee, J.; Kim, J.; Jo, S.; Kim, Y.J.; Baek, J.E.; Kwon, E.-S.; Lee, K.-P.; Yang, S.; Kwon, K.-S.; et al. Pancreatic Adenocarcinoma
Up-Regulated Factor (PAUF) Enhances the Accumulation and Functional Activity of Myeloid-Derived Suppressor Cells (MDSCs)
in Pancreatic Cancer. Oncotarget 2016, 7, 51840–51853. [CrossRef]
49. Markowitz, J.; Brooks, T.R.; Duggan, M.C.; Paul, B.K.; Pan, X.; Wei, L.; Abrams, Z.; Luedke, E.; Lesinski, G.B.; Mundy-Bosse, B.;
et al. Patients with Pancreatic Adenocarcinoma Exhibit Elevated Levels of Myeloid-Derived Suppressor Cells upon Progression
of Disease. Cancer Immunol. Immunother. 2015, 64, 149–159. [CrossRef]
50. Yang, X.; Lu, Y.; Hang, J.; Zhang, J.; Zhang, T.; Huo, Y.; Liu, J.; Lai, S.; Luo, D.; Wang, L.; et al. Lactate-Modulated Immunosup-
pression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. Cancer Immunol. Res. 2020,
8, 1440–1451. [CrossRef]
51. Isherwood, J.; Arshad, A.; Chung, W.Y.; Runau, F.; Cooke, J.; Pollard, C.; Howells, L.; Fishwick, J.; Thompson, J.; Metcalfe, M.;
et al. Myeloid Derived Suppressor Cells Are Reduced and T Regulatory Cells Stabilised in Patients with Advanced Pancreatic
Cancer Treated with Gemcitabine and Intravenous Omega 3. Ann. Transl. Med. 2020, 8, 172. [CrossRef]
52. Ijichi, H.; Chytil, A.; Gorska, A.E.; Aakre, M.E.; Bierie, B.; Tada, M.; Mohri, D.; Miyabayashi, K.; Asaoka, Y.; Maeda, S.;
et al. Inhibiting Cxcr2 Disrupts Tumor-Stromal Interactions and Improves Survival in a Mouse Model of Pancreatic Ductal
Adenocarcinoma. J. Clin. Invest. 2011, 121, 4106–4117. [CrossRef] [PubMed]
53. Cappello, P.; Tonoli, E.; Curto, R.; Giordano, D.; Giovarelli, M.; Novelli, F. Anti-α-Enolase Antibody Limits the Invasion of
Myeloid-Derived Suppressor Cells and Attenuates Their Restraining Effector T Cell Response. Oncoimmunology 2016, 5, e1112940.
[CrossRef] [PubMed]
54. Nagaraj, S.; Youn, J.-I.; Weber, H.; Iclozan, C.; Lu, L.; Cotter, M.J.; Meyer, C.; Becerra, C.R.; Fishman, M.; Antonia, S.; et al.
Anti-Inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer.
Clin. Cancer Res. 2010, 16, 1812–1823. [CrossRef] [PubMed]
55. Ling, X.; Konopleva, M.; Zeng, Z.; Ruvolo, V.; Stephens, L.C.; Schober, W.; McQueen, T.; Dietrich, M.; Madden, T.L.; Andreeff, M.
The Novel Triterpenoid C-28 Methyl Ester of 2-Cyano-3, 12-Dioxoolen-1, 9-Dien-28-Oic Acid Inhibits Metastatic Murine Breast
Tumor Growth through Inactivation of STAT3 Signaling. Cancer Res. 2007, 67, 4210–4218. [CrossRef] [PubMed]
56. Martinez-Useros, J.; Garcia-Foncillas, J. Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed.
Res. Int. 2016, 2016, 4873089. [CrossRef] [PubMed]
57. Martinez-Useros, J.; Garcia-Foncillas, J. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker
for Pancreatic Cancer. Biomed. Res. Int. 2016, 2016, 1869304. [CrossRef]
58. Sabharwal, S.S.; Schumacker, P.T. Mitochondrial ROS in Cancer: Initiators, Amplifiers or an Achilles’ Heel? Nat. Rev. Cancer 2014,
14, 709–721. [CrossRef] [PubMed]
59. Bailey, P.; Chang, D.K.; Nones, K.; Johns, A.L.; Patch, A.-M.; Gingras, M.-C.; Miller, D.K.; Christ, A.N.; Bruxner, T.J.C.; Quinn,
M.C.; et al. Genomic Analyses Identify Molecular Subtypes of Pancreatic Cancer. Nature 2016, 531, 47–52. [CrossRef]
60. Moffitt, R.A.; Marayati, R.; Flate, E.L.; Volmar, K.E.; Loeza, S.G.H.; Hoadley, K.A.; Rashid, N.U.; Williams, L.A.; Eaton, S.C.; Chung,
A.H.; et al. Virtual Microdissection Identifies Distinct Tumor- and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma.
Nat. Genet. 2015, 47, 1168–1178. [CrossRef]
61. Collisson, E.A.; Sadanandam, A.; Olson, P.; Gibb, W.J.; Truitt, M.; Gu, S.; Cooc, J.; Weinkle, J.; Kim, G.E.; Jakkula, L.; et al. Subtypes
of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy. Nat. Med. 2011, 17, 500–503. [CrossRef]
Cancers 2021, 13, 322 16 of 18
62. Feng, Y.-F.; Chen, J.-Y.; Chen, H.-Y.; Wang, T.-G.; Shi, D.; Lu, Y.-F.; Pan, Y.; Shao, C.-W.; Yu, R.-S. 110 Patients with Adenosquamous
Carcinomas of the Pancreas (PASC): Imaging Differentiation of Small (≤3 Cm) versus Large (>3 Cm) Tumors. Abdom. Radiol. (N.
Y.) 2019, 44, 2466–2473. [CrossRef] [PubMed]
63. Niger, M.; Prisciandaro, M.; Antista, M.; Monica, M.A.T.; Cattaneo, L.; Prinzi, N.; Manglaviti, S.; Nichetti, F.; Brambilla, M.;
Torchio, M.; et al. One Size Does Not Fit All for Pancreatic Cancers: A Review on Rare Histologies and Therapeutic Approaches.
World J. Gastrointest. Oncol. 2020, 12, 833–849. [CrossRef] [PubMed]
64. Fang, Y.; Su, Z.; Xie, J.; Xue, R.; Ma, Q.; Li, Y.; Zhao, Y.; Song, Z.; Lu, X.; Li, H.; et al. Genomic Signatures of Pancreatic
Adenosquamous Carcinoma (PASC). J. Pathol. 2017, 243, 155–159. [CrossRef] [PubMed]
65. Bosman, F.T.; Carneiro, F.; Hruban, R.H.; Theise, N.D. WHO Classification of Tumours of the Digestive System—NLM Catalog—NCBI;
IARC Press: Lyon, France, 2010.
66. Cancer Genome Atlas Research Network. By The Cancer Genome Atlas Research Network. Integrated Genomic Characterization
of Pancreatic Ductal Adenocarcinoma. Cancer Cell 2017, 32, 185–203. [CrossRef] [PubMed]
67. Engelmann, D.; Pützer, B.M. Emerging from the Shade of P53 Mutants: N-Terminally Truncated Variants of the P53 Family in
EMT Signaling and Cancer Progression. Sci. Signal 2014, 7, re9. [CrossRef] [PubMed]
68. Miller, B.W.; Morton, J.P.; Pinese, M.; Saturno, G.; Jamieson, N.B.; McGhee, E.; Timpson, P.; Leach, J.; McGarry, L.; Shanks, E.;
et al. Targeting the LOX/Hypoxia Axis Reverses Many of the Features That Make Pancreatic Cancer Deadly: Inhibition of LOX
Abrogates Metastasis and Enhances Drug Efficacy. EMBO Mol. Med. 2015, 7, 1063–1076. [CrossRef]
69. Hosein, A.N.; Brekken, R.A.; Maitra, A. Pancreatic Cancer Stroma: An Update on Therapeutic Targeting Strategies. Nat. Rev.
Gastroenterol. Hepatol. 2020, 17, 487–505. [CrossRef]
70. Bristow, R.G.; Hill, R.P. Hypoxia and Metabolism. Hypoxia, DNA Repair and Genetic Instability. Nat. Rev. Cancer 2008, 8, 180–192.
[CrossRef]
71. Kitamoto, S.; Yokoyama, S.; Higashi, M.; Yamada, N.; Takao, S.; Yonezawa, S. MUC1 Enhances Hypoxia-Driven Angiogenesis
through the Regulation of Multiple Proangiogenic Factors. Oncogene 2013, 32, 4614–4621. [CrossRef]
72. Biankin, A.V.; Kench, J.G.; Colvin, E.K.; Segara, D.; Scarlett, C.J.; Nguyen, N.Q.; Chang, D.K.; Morey, A.L.; Lee, C.-S.; Pinese, M.;
et al. Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer. Gastroenterology
2009, 137, 558–568. [CrossRef]
73. Mews, P.; Phillips, P.; Fahmy, R.; Korsten, M.; Pirola, R.; Wilson, J.; Apte, M. Pancreatic Stellate Cells Respond to Inflammatory
Cytokines: Potential Role in Chronic Pancreatitis. Gut 2002, 50, 535–541. [CrossRef] [PubMed]
74. Masamune, A.; Satoh, M.; Kikuta, K.; Suzuki, N.; Shimosegawa, T. Activation of JAK-STAT Pathway Is Required for Platelet-
Derived Growth Factor-Induced Proliferation of Pancreatic Stellate Cells. World J. Gastroenterol. 2005, 11, 3385–3391. [CrossRef]
[PubMed]
75. Somerville, T.D.; Biffi, G.; Daßler-Plenker, J.; Hur, S.K.; He, X.-Y.; Vance, K.E.; Miyabayashi, K.; Xu, Y.; Maia-Silva, D.; Klingbeil, O.;
et al. Squamous Trans-Differentiation of Pancreatic Cancer Cells Promotes Stromal Inflammation. Elife 2020, 9, e53381. [CrossRef]
[PubMed]
76. Öhlund, D.; Handly-Santana, A.; Biffi, G.; Elyada, E.; Almeida, A.S.; Ponz-Sarvise, M.; Corbo, V.; Oni, T.E.; Hearn, S.A.; Lee, E.J.;
et al. Distinct Populations of Inflammatory Fibroblasts and Myofibroblasts in Pancreatic Cancer. J. Exp. Med. 2017, 214, 579–596.
[CrossRef]
77. Lankadasari, M.B.; Mukhopadhyay, P.; Mohammed, S.; Harikumar, K.B. TAMing Pancreatic Cancer: Combat with a Double
Edged Sword. Mol. Cancer 2019, 18, 48. [CrossRef]
78. Ireland, L.; Santos, A.; Ahmed, M.S.; Rainer, C.; Nielsen, S.R.; Quaranta, V.; Weyer-Czernilofsky, U.; Engle, D.D.; Perez-Mancera,
P.A.; Coupland, S.E.; et al. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.
Cancer Res. 2016, 76, 6851–6863. [CrossRef]
79. Dalin, S.; Sullivan, M.R.; Lau, A.N.; Grauman-Boss, B.; Mueller, H.S.; Kreidl, E.; Fenoglio, S.; Luengo, A.; Lees, J.A.; Vander
Heiden, M.G.; et al. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res. 2019, 79,
5723–5733. [CrossRef]
80. Al-Assar, O.; Demiciorglu, F.; Lunardi, S.; Gaspar-Carvalho, M.M.; McKenna, W.G.; Muschel, R.M.; Brunner, T.B. Contextual
Regulation of Pancreatic Cancer Stem Cell Phenotype and Radioresistance by Pancreatic Stellate Cells. Radiother. Oncol. 2014, 111,
243–251. [CrossRef]
81. Panni, R.Z.; Sanford, D.E.; Belt, B.A.; Mitchem, J.B.; Worley, L.A.; Goetz, B.D.; Mukherjee, P.; Wang-Gillam, A.; Link, D.C.;
Denardo, D.G.; et al. Tumor-Induced STAT3 Activation in Monocytic Myeloid-Derived Suppressor Cells Enhances Stemness and
Mesenchymal Properties in Human Pancreatic Cancer. Cancer Immunol. Immunother. 2014, 63, 513–528. [CrossRef]
82. Feig, C.; Jones, J.O.; Kraman, M.; Wells, R.J.B.; Deonarine, A.; Chan, D.S.; Connell, C.M.; Roberts, E.W.; Zhao, Q.; Caballero, O.L.;
et al. Targeting CXCL12 from FAP-Expressing Carcinoma-Associated Fibroblasts Synergizes with Anti-PD-L1 Immunotherapy in
Pancreatic Cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 20212–20217. [CrossRef]
83. Jenkins, R.W.; Barbie, D.A.; Flaherty, K.T. Mechanisms of Resistance to Immune Checkpoint Inhibitors. Br. J. Cancer 2018, 118,
9–16. [CrossRef]
84. Holmgaard, R.B.; Zamarin, D.; Munn, D.H.; Wolchok, J.D.; Allison, J.P. Indoleamine 2,3-Dioxygenase Is a Critical Resistance
Mechanism in Antitumor T Cell Immunotherapy Targeting CTLA-4. J. Exp. Med. 2013, 210, 1389–1402. [CrossRef] [PubMed]
Cancers 2021, 13, 322 17 of 18
85. Blair, A.B.; Kleponis, J.; Thomas, D.L.; Muth, S.T.; Murphy, A.G.; Kim, V.; Zheng, L. IDO1 Inhibition Potentiates Vaccine-Induced
Immunity against Pancreatic Adenocarcinoma. J. Clin. Investig. 2019, 129, 1742–1755. [CrossRef] [PubMed]
86. Peng, J.; Sun, B.-F.; Chen, C.-Y.; Zhou, J.-Y.; Chen, Y.-S.; Chen, H.; Liu, L.; Huang, D.; Jiang, J.; Cui, G.-S.; et al. Single-Cell RNA-Seq
Highlights Intra-Tumoral Heterogeneity and Malignant Progression in Pancreatic Ductal Adenocarcinoma. Cell Res. 2019, 29,
725–738. [CrossRef] [PubMed]
87. Shi, S.; Xu, J.; Zhang, B.; Ji, S.; Xu, W.; Liu, J.; Jin, K.; Liang, D.; Liang, C.; Liu, L.; et al. VEGF Promotes Glycolysis in Pancreatic
Cancer via HIF1α Up-Regulation. Curr. Mol. Med. 2016, 16, 394–403. [CrossRef]
88. Hale, M.A.; Kagami, H.; Shi, L.; Holland, A.M.; Elsässer, H.-P.; Hammer, R.E.; MacDonald, R.J. The Homeodomain Protein PDX1
Is Required at Mid-Pancreatic Development for the Formation of the Exocrine Pancreas. Dev. Biol. 2005, 286, 225–237. [CrossRef]
89. Patra, K.C.; Bardeesy, N.; Mizukami, Y. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of
Intraductal Papillary Mucinous Neoplasm. Clin. Transl. Gastroenterol. 2017, 8, e86. [CrossRef]
90. Baker, M.L.; Seeley, E.S.; Pai, R.; Suriawinata, A.A.; Mino-Kenudson, M.; Zamboni, G.; Klöppel, G.; Longnecker, D.S. Invasive
Mucinous Cystic Neoplasms of the Pancreas. Exp. Mol. Pathol. 2012, 93, 345–349. [CrossRef]
91. Martinelli, P.; Carrillo-de Santa Pau, E.; Cox, T.; Sainz, B.; Dusetti, N.; Greenhalf, W.; Rinaldi, L.; Costello, E.; Ghaneh, P.; Malats,
N.; et al. GATA6 Regulates EMT and Tumour Dissemination, and Is a Marker of Response to Adjuvant Chemotherapy in
Pancreatic Cancer. Gut 2017, 66, 1665–1676. [CrossRef]
92. Suh, H.; Pillai, K.; Morris, D.L. Mucins in Pancreatic Cancer: Biological Role, Implications in Carcinogenesis and Applications in
Diagnosis and Therapy. Am. J. Cancer Res. 2017, 7, 1372–1383.
93. Pompella, L.; Tirino, G.; Pappalardo, A.; Caterino, M.; Ventriglia, A.; Nacca, V.; Orditura, M.; Ciardiello, F.; De Vita, F. Pancreatic
Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. Int. J. Mol. Sci. 2020, 21, 2814. [CrossRef]
[PubMed]
94. Cheng, H.; Luo, G.; Jin, K.; Fan, Z.; Huang, Q.; Gong, Y.; Xu, J.; Yu, X.; Liu, C. Kras Mutation Correlating with Circulating
Regulatory T Cells Predicts the Prognosis of Advanced Pancreatic Cancer Patients. Cancer Med. 2020, 9, 2153–2159. [CrossRef]
[PubMed]
95. Bauer, C.A.; Kim, E.Y.; Marangoni, F.; Carrizosa, E.; Claudio, N.M.; Mempel, T.R. Dynamic Treg Interactions with Intratumoral
APCs Promote Local CTL Dysfunction. J. Clin. Invest. 2014, 124, 2425–2440. [CrossRef] [PubMed]
96. Trivedi, P.M.; Fynch, S.; Kennedy, L.M.; Chee, J.; Krishnamurthy, B.; O’Reilly, L.A.; Strasser, A.; Kay, T.W.H.; Thomas, H.E. Soluble
FAS Ligand Is Not Required for Pancreatic Islet Inflammation or Beta-Cell Destruction in Non-Obese Diabetic Mice. Cell Death
Discov. 2019, 5, 136. [CrossRef] [PubMed]
97. Sideras, K.; Braat, H.; Kwekkeboom, J.; van Eijck, C.H.; Peppelenbosch, M.P.; Sleijfer, S.; Bruno, M. Role of the Immune System in
Pancreatic Cancer Progression and Immune Modulating Treatment Strategies. Cancer Treat. Rev. 2014, 40, 513–522. [CrossRef]
[PubMed]
98. Jiao, Y.; Yonescu, R.; Offerhaus, G.J.A.; Klimstra, D.S.; Maitra, A.; Eshleman, J.R.; Herman, J.G.; Poh, W.; Pelosof, L.; Wolfgang, C.L.;
et al. Whole-Exome Sequencing of Pancreatic Neoplasms with Acinar Differentiation. J. Pathol. 2014, 232, 428–435. [CrossRef]
99. Furukawa, T.; Sakamoto, H.; Takeuchi, S.; Ameri, M.; Kuboki, Y.; Yamamoto, T.; Hatori, T.; Yamamoto, M.; Sugiyama, M.; Ohike,
N.; et al. Whole Exome Sequencing Reveals Recurrent Mutations in BRCA2 and FAT Genes in Acinar Cell Carcinomas of the
Pancreas. Sci. Rep. 2015, 5, 8829. [CrossRef]
100. Von Figura, G.; Morris, J.P.; Wright, C.V.E.; Hebrok, M. Nr5a2 Maintains Acinar Cell Differentiation and Constrains Oncogenic
Kras-Mediated Pancreatic Neoplastic Initiation. Gut 2014, 63, 656–664. [CrossRef]
101. Hale, M.A.; Swift, G.H.; Hoang, C.Q.; Deering, T.G.; Masui, T.; Lee, Y.-K.; Xue, J.; MacDonald, R.J. The Nuclear Hormone Receptor
Family Member NR5A2 Controls Aspects of Multipotent Progenitor Cell Formation and Acinar Differentiation during Pancreatic
Organogenesis. Development 2014, 141, 3123–3133. [CrossRef]
102. Mathison, A.; Liebl, A.; Bharucha, J.; Mukhopadhyay, D.; Lomberk, G.; Shah, V.; Urrutia, R. Pancreatic Stellate Cell Models for
Transcriptional Studies of Desmoplasia-Associated Genes. Pancreatology 2010, 10, 505–516. [CrossRef]
103. Erkan, M.; Reiser-Erkan, C.; Michalski, C.W.; Deucker, S.; Sauliunaite, D.; Streit, S.; Esposito, I.; Friess, H.; Kleeff, J. Cancer-Stellate
Cell Interactions Perpetuate the Hypoxia-Fibrosis Cycle in Pancreatic Ductal Adenocarcinoma. Neoplasia 2009, 11, 497–508.
[CrossRef] [PubMed]
104. Wang, Z.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A.S.; Kong, D.; Sarkar, F.H. Pancreatic Cancer: Understanding and Overcoming
Chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 27–33. [CrossRef] [PubMed]
105. Mekapogu, A.R.; Pothula, S.P.; Pirola, R.C.; Wilson, J.S.; Apte, M.V. Multifunctional Role of Pancreatic Stellate Cells in Pancreatic
Cancer. Ann. Pancreat. Cancer 2019, 2. [CrossRef]
106. Franses, J.W.; Basar, O.; Kadayifci, A.; Yuksel, O.; Choz, M.; Kulkarni, A.S.; Tai, E.; Vo, K.D.; Arora, K.S.; Desai, N.; et al. Improved
Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. Oncologist 2018, 23, 1260.
[CrossRef]
107. Lahat, G.; Lubezky, N.; Loewenstein, S.; Nizri, E.; Gan, S.; Pasmanik-Chor, M.; Hayman, L.; Barazowsky, E.; Ben-Haim, M.;
Klausner, J.M. Epithelial-to-Mesenchymal Transition (EMT) in Intraductal Papillary Mucinous Neoplasm (IPMN) Is Associated
with High Tumor Grade and Adverse Outcomes. Ann. Surg. Oncol. 2014, 21, S750–S757. [CrossRef]
108. Rooney, M.S.; Shukla, S.A.; Wu, C.J.; Getz, G.; Hacohen, N. Molecular and Genetic Properties of Tumors Associated with Local
Immune Cytolytic Activity. Cell 2015, 160, 48–61. [CrossRef]
Cancers 2021, 13, 322 18 of 18
109. Yachida, S.; Jones, S.; Bozic, I.; Antal, T.; Leary, R.; Fu, B.; Kamiyama, M.; Hruban, R.H.; Eshleman, J.R.; Nowak, M.A.; et al.
Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer. Nature 2010, 467, 1114–1117. [CrossRef]
110. A Phase I/II Study of a MUC1 Peptide Pulsed Autologous Dendritic Cell Vaccine as Adjuvant Therapy in Patients with Resected
Pancreatic and Biliary Tumors—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/19129927/ (accessed on 11
November 2020).
111. Hu, G.; He, N.; Cai, C.; Cai, F.; Fan, P.; Zheng, Z.; Jin, X. HDAC3 Modulates Cancer Immunity via Increasing PD-L1 Expression in
Pancreatic Cancer. Pancreatology 2019, 19, 383–389. [CrossRef]
112. Park, H.; Bang, J.-H.; Nam, A.-R.; Eun Park, J.; Hua Jin, M.; Bang, Y.-J.; Oh, D.-Y. Prognostic Implications of Soluble Programmed
Death-Ligand 1 and Its Dynamics during Chemotherapy in Unresectable Pancreatic Cancer. Sci. Rep. 2019, 9, 11131. [CrossRef]
113. Saka, D.; Gökalp, M.; Piyade, B.; Cevik, N.C.; Arik Sever, E.; Unutmaz, D.; Ceyhan, G.O.; Demir, I.E.; Asimgil, H. Mechanisms of
T-Cell Exhaustion in Pancreatic Cancer. Cancers 2020, 12, 2274. [CrossRef]
114. Yazdanifar, M.; Zhou, R.; Grover, P.; Williams, C.; Bose, M.; Moore, L.J.; Wu, S.-T.; Maher, J.; Dreau, D.; Mukherjee, A.P.
Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-TMUC1-CAR T Cell Treatment against Pancreatic
Ductal Adenocarcinoma. Cells 2019, 8, 1070. [CrossRef] [PubMed]
115. Beatty, G.L.; Haas, A.R.; Maus, M.V.; Torigian, D.A.; Soulen, M.C.; Plesa, G.; Chew, A.; Zhao, Y.; Levine, B.L.; Albelda, S.M.; et al.
Mesothelin-Specific Chimeric Antigen Receptor MRNA-Engineered T Cells Induce Anti-Tumor Activity in Solid Malignancies.
Cancer Immunol. Res. 2014, 2, 112–120. [CrossRef] [PubMed]
116. Diaz Sanchez, A.; Ponferrada Diaz, Á.; Senosiain Labiano, M.; Huerta Madrigal, A. Hemorragia digestiva alta como presentación
de un carcinoma acinar pancreático. Gastroenterol. Hepatol. 2006, 29, 380. [CrossRef]
117. Kordes, C.; Sawitza, I.; Götze, S.; Häussinger, D. Stellate Cells from Rat Pancreas Are Stem Cells and Can Contribute to Liver
Regeneration. PLoS ONE 2012, 7, e51878. [CrossRef] [PubMed]
118. Tang, D.; Wang, D.; Yuan, Z.; Xue, X.; Zhang, Y.; An, Y.; Chen, J.; Tu, M.; Lu, Z.; Wei, J.; et al. Persistent Activation of Pancreatic
Stellate Cells Creates a Microenvironment Favorable for the Malignant Behavior of Pancreatic Ductal Adenocarcinoma. Int. J.
Cancer 2013, 132, 993–1003. [CrossRef]
119. Masamune, A.; Kikuta, K.; Watanabe, T.; Satoh, K.; Hirota, M.; Shimosegawa, T. Hypoxia Stimulates Pancreatic Stellate Cells
to Induce Fibrosis and Angiogenesis in Pancreatic Cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G709–G717.
[CrossRef]
120. Miyamoto, H.; Murakami, T.; Tsuchida, K.; Sugino, H.; Miyake, H.; Tashiro, S. Tumor-Stroma Interaction of Human Pancreatic
Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins.
Pancreas 2004, 28, 38–44. [CrossRef]
121. Tian, B.; Wong, W.Y.; Uger, M.D.; Wisniewski, P.; Chao, H. Development and Characterization of a Camelid Single Domain
Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2. Front. Immunol. 2017, 8, 956. [CrossRef]
122. Le, D.T.; Wang-Gillam, A.; Picozzi, V.; Greten, T.F.; Crocenzi, T.; Springett, G.; Morse, M.; Zeh, H.; Cohen, D.; Fine, R.L.; et al.
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines
for Metastatic Pancreatic Cancer. J. Clin. Oncol. 2015, 33, 1325–1333. [CrossRef]
123. Roccaro, A.M.; Sacco, A.; Purschke, W.G.; Moschetta, M.; Buchner, K.; Maasch, C.; Zboralski, D.; Zöllner, S.; Vonhoff, S.; Mishima,
Y.; et al. SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy. Cell Rep. 2014, 9, 118–128. [CrossRef]
